Legal Disclaimer

This page provides general legal orientation for South Korea, not legal advice. Regulations change frequently. Always verify current rules with MFDS and consult a qualified professional.

Peptide Legal Status in South Korea

Moderate

South Korea regulates pharmaceuticals through MFDS under the Pharmaceutical Affairs Act. GLP-1 agonists are MFDS-approved and in extremely high demand — particularly for weight management, leading to periodic shortages. Wegovy launched in Korea in 2024 and saw rapid uptake. Korea's National Health Insurance (NHIS) generally does not cover obesity medications for weight loss (they are considered lifestyle/appearance drugs), though diabetes indications are covered. Korea has a sophisticated pharmaceutical market with strong domestic manufacturing and strict quality standards. Telehealth (비대면진료) was expanded during COVID-19 but permanent legislation remains under debate.

Regulator

MFDS (Ministry of Food and Drug Safety) — Official website

Key Facts

Regulatory Stance
moderate
Compounding Allowed
Yes
Telehealth Prescribing
Yes

Compounding Pharmacy Rules

Pharmacy compounding (조제 — prescription preparation) is permitted by licensed pharmacists under the Pharmaceutical Affairs Act. Compounding must follow Korean Pharmacopoeia (KP) standards. GMP standards apply to manufacturing facilities. Hospital pharmacies in larger institutions perform most specialized compounding.

Telehealth Prescribing

Telehealth (비대면진료 — non-face-to-face treatment) was temporarily permitted during COVID-19 and has been maintained on a transitional basis while permanent legislation is debated. The Korean Medical Association has opposed permanent expansion. Current rules permit telemedicine with restrictions — initial consultations are expected to be in-person. Prescribing GLP-1s typically requires in-person evaluation.

Peptide Categories in South Korea

Approved

Semaglutide — Ozempic (T2D), Wegovy (weight management, launched 2024), Rybelsus (oral, T2D). Tirzepatide — Mounjaro (T2D). Liraglutide — Saxenda (weight management), Victoza (T2D). All MFDS-approved, prescription-only (전문의약품). NHIS covers diabetes indications; weight loss medications are typically not reimbursed (self-pay, 비급여).

Research / Unapproved

BPC-157, GHRPs — not MFDS-approved. Import, sale, and supply of unapproved pharmaceuticals is prohibited. MFDS monitors online sales and may coordinate with Korea Customs Service (KCS) to intercept unauthorized imports.

Banned / Restricted

Unapproved pharmaceuticals. Narcotics and psychotropic substances regulated under the Narcotics Control Act. KCS may seize unauthorized pharmaceutical imports. Penalties for illegal pharmaceutical sales include fines and imprisonment.

Key Legislation

  • Pharmaceutical Affairs Act (약사법)
  • Narcotics Control Act (마약류 관리에 관한 법률)
  • Medical Service Act (의료법)

Peptides in South Korea: FAQ

Sources

Peptide Laws in Other Countries

United KingdomCanadaAustraliaEuropean UnionSingaporeUnited Arab EmiratesNew ZealandGermanyNetherlandsFranceSpainHong KongJapan